Findings

What do systematic reviews say?

4,721 questions · 19,640 findings · 2,039 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,754 · 19.1%GRADE not reported 1,273 · 6.5%Very low 4,859 · 24.7%Low 5,568 · 28.4%Moderate 3,240 · 16.5%High 946 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Complications · adults with PAC or PACG, and previous PI

1 finding from 1 review

Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Low

Intervention not reported

Further surgical or laser interventions · adults with PAC or PACG, and previous PI

1 finding from 1 review

Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Low

Intervention not reported

Quality of life measures · adults with PAC or PACG, and previous PI

The review found no eligible studies for this question.

1 finding from 1 review

Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Anterior chamber morphology · adults with PAC or PACG, and previous PI

1 finding from 1 review

Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Intervention not reported

Disease progression · adults with PACS or PAC, and previous PI

The review found no eligible studies for this question.

1 finding from 1 review

Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

IOP · adults with PACS or PAC, and previous PI

1 finding from 1 review

Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Surgery for Bell's palsy vs medical treatment (oral prednisolone) or no treatment

Complete recovery of facial nerve function at 12 months Defined as: complete recovery HB grade I. · Bell's palsy

It is very uncertain whether surgery for Bell's palsy changes complete recovery of facial nerve function at 12 months Defined as:… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).

1 finding from 1 review

Surgical interventions for the early management of Bell's palsy 2021 · Cochrane Headline outcomes only
RR 0.76
2 studies · 57 participants
Very low

Surgery for Bell's palsy vs medical treatment (oral prednisolone) or no treatment

Complications and side effects · Bell's palsy

It is very uncertain whether surgery for Bell's palsy changes side effects and complications of treatmentMeasured by clinical… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).

1 finding from 1 review

Surgical interventions for the early management of Bell's palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 57 participants
Very low

Orlistat vs placebo

Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1488 participants
Low

Phentermine/topiramate vs placebo

Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 0.85 [0.49, 1.48]
1 study · 1305 participants
Low

Phentermine/topiramate vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.13 [1.08, 1.2]
1 study · 1305 participants
Low

Phentermine/topiramate vs placebo

Change in body weight as compared to placebo (%) from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 772 participants
Low

Naltrexone/bupropion vs placebo

Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Naltrexone/bupropion showed no clear difference in total mortality compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 0.99 [0.7, 1.4]
1 study · 8283 participants
Moderate

Naltrexone/bupropion vs placebo

Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.11 [0.87, 1.41]
1 study · 8283 participants
Low

Naltrexone/bupropion vs placebo

Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.05 [0.96, 1.14]
1 study · 8283 participants
Moderate

Naltrexone/bupropion vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.69 [1.58, 1.8]
1 study · 8283 participants
Moderate

Orlistat vs placebo

Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1811 participants
Very low

Naltrexone/bupropion vs placebo

Change in body weight as compared to placebo [kg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8283 participants
Moderate

Orlistat vs placebo

Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.45 [1.1, 1.91]
3 studies · 1476 participants
Moderate

Orlistat vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.13 [0.84, 1.54]
2 studies · 1386 participants
Very low